Insights

Innovative Portfolio Growth Amylin specializes in developing therapies for metabolic diseases like diabetes and obesity, representing a growing market opportunity given the increasing prevalence of these health issues worldwide.

Strong Industry Position As a wholly owned subsidiary of Bristol-Myers Squibb with a revenue between $500 million and $1 billion, Amylin demonstrates a solid financial foundation and credibility within the pharmaceutical industry.

Expanding Market Presence With a team of up to 5,000 employees and an active pipeline, Amylin is positioned for expansion in metabolic therapy sectors, offering potential for partnerships and collaborations.

Technological Innovation Amylin's focus on discovering and developing innovative therapies suggests opportunities for technology providers supporting pharmaceutical R&D and biotech innovations.

Strategic Acquisition Backing Having been acquired by Bristol-Myers Squibb for $7 billion, Amylin benefits from extensive resources and market reach, providing a platform for future growth and sales of cutting-edge healthcare solutions.

Similar companies to Amylin

Amylin Tech Stack

Media & News

Bristol-Myers Squibb Co acquired Amylin for $7B on Jan 1st '12.
Dr. Jonathan Rothbard, CannBioRx's Chief Scientific Officer, was involved in establishing Amylin Pharmaceuticals, which was acquired by Bristol-Myers Squibb in 2012 for $7 billion.
Jul 26, 2019 | www.prnewswire.com

Amylin's Email Address Formats

Amylin uses at least 1 format(s):

Amylin Email Formats	Example	Percentage
First.Last@amylin.com	John.Doe@amylin.com	85%
FLast@amylin.com	JDoe@amylin.com	12%
First@amylin.com	John@amylin.com	2%
Last@amylin.com	Doe@amylin.com	1%

Frequently Asked Questions

What is Amylin's phone number?

You can contact Amylin's main corporate office by phone at

+1-858-552-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Amylin's stock symbol?

Amylin is a publicly traded company; the company's stock symbol is AMLN.

What is Amylin's official website and social media links?

Amylin's official website is amylin.com and has social profiles on LinkedIn Crunchbase.

What is Amylin's SIC code NAICS code?

Amylin's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Amylin have currently?

As of December 2025, Amylin has approximately 1K employees across 5 continents, including North AmericaOceaniaAfrica. Key team members include Chief Technology Officer: R. S.Chief Technology Officer: W. W.Vice President Medical Affairs: S. B.. Explore Amylin's employee directory with LeadIQ.

What industry does Amylin belong to?

Amylin operates in the Pharmaceutical Manufacturing industry.

What is Amylin's email format?

Amylin's email format typically follows the pattern of First.Last@amylin.com. Find more Amylin email formats with LeadIQ.

When was Amylin founded?

Amylin was founded in 1987.

Amylin

Q: What is Amylin's official website and social media links?

Amylin's official website is amylin.com. Amylin has social profiles on LinkedIn.

Q: How many employees does Amylin have currently?

Amylin has approximately 1K employees.

Pharmaceutical ManufacturingCalifornia, United States1001-5000 Employees

Amylin Pharmaceuticals, a wholly owned subsidiary of Bristol- Myers Squibb, is an exceptional company of extraordinary people. Their willingness to challenge conventional thinking as much as they challenge themselves, their resolve, resiliency and passion for the patient are improving the lives of millions.

The men and women of Amylin are discovering, developing, and bringing to market innovative therapies with life-changing potential for people struggling with diabetes and obesity—merging epidemics that are fast becoming the major health crises of our lifetime. In the process, they are building an exciting new franchise in the treatment of metabolic disease and a pipeline of possibilities for future healthcare solutions.